Loading...
Market
Regeneron Outperformance of S&P 500 by End of 2024
5
Regeneron Pharmaceuticals•Mammoth Biosciences•Brisbane•Jennifer Doudna•Regeneron•Intellia Therapeutics
Resolution / Starting Odds
Yes • 50%
No • 50%
Standard financial market data sources like Bloomberg or Reuters
Story
Regeneron Invests $100M in CRISPR Therapies with Mammoth Biosciences
Apr 25, 2024, 01:45 PM
Regeneron Pharmaceuticals has expanded its presence in the field of gene editing by entering into a significant partnership with Mammoth Biosciences, a Brisbane, CA-based biotech company co-founded by CRISPR pioneer Jennifer Doudna. The collaboration focuses on developing in vivo CRISPR-based gene editing therapies aimed at multiple tissues and cell types. Regeneron will make an upfront payment and equity investment totaling $100 million, along with additional milestone payments. This deal is part of Regeneron's broader strategy to enhance its genetic medicine portfolio, which includes other initiatives like a longstanding research agreement with Intellia Therapeutics targeting the rare disease transthyretin amyloidosis and the acquisition of a gene therapy biotech.
View original story
Similar markets
Increase in Regeneron's stock price • 50%
Decrease in Regeneron's stock price • 50%
Yes • 50%
No • 50%
Outperforms S&P 500 • 33%
Underperforms S&P 500 • 33%
Performs in line with S&P 500 • 34%
Outperform • 33%
Underperform • 33%
Match • 33%
Stock price increases by over 20% • 33%
Stock price increases by 10-20% • 33%
Stock price increases by less than 10% • 34%
Outperforms S&P 500 • 50%
Underperforms S&P 500 • 50%
Outperforms S&P 500 • 50%
Underperforms or matches S&P 500 • 50%
